Locametz Unia Europejska - polski - EMA (European Medicines Agency)

locametz

novartis europharm limited  - gozetotide - obrazowanie radionuklidami - diagnostyczne radiofarmaceutyki - ten produkt leczniczy jest przeznaczony wyłącznie do celów diagnostycznych. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Pluvicto Unia Europejska - polski - EMA (European Medicines Agency)

pluvicto

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - nowotwory gruczołu krokowego, odpornego Łożysko - terapeutyczne radiofarmaceutyki - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Pylclari Unia Europejska - polski - EMA (European Medicines Agency)

pylclari

curium pet france - piflufolastat (18f) - nowotwory stercza - diagnostyczne radiofarmaceutyki - ten produkt leczniczy jest przeznaczony wyłącznie do celów diagnostycznych. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

Seffalair Spiromax Unia Europejska - polski - EMA (European Medicines Agency)

seffalair spiromax

teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - preparaty do obturacyjne choroby dróg oddechowych, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Camcevi Unia Europejska - polski - EMA (European Medicines Agency)

camcevi

accord healthcare s.l.u. - leuprorelin mesilate - nowotwory stercza - terapia endokrynologiczna - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.